Brind.

Bank of America downgraded LENZ Therapeutics' stock on September 2, 2026, citing slow commercial launch.

2 reports, 1 independent Updated Oct 1
Gone quiet
Reports
2
Developments
2
Repetition
0%

New informationRepeats or wire copies

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Bank of America downgraded LENZ Therapeutics' stock on September 2, 2026, citing slow commercial launch.

Who's involved

What this event is mainly about
Bank of America

How it developed

Newest first. Tap a step to see who reported it.
  1. BoA lowered price target for LENZ Therapeutics following previous downgrade.1 source
  2. BoA downgraded LENZ Therapeutics stock due to slow commercial launch.1 source

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped